New trial of medicinal cannabis for chemotherapy-related nausea and vomiting
CTC is starting up a new trial to assess the use of medicinal
cannabis to prevent nausea in people undergoing chemotherapy whose
symptoms are not controlled by current drugs.
The trial is part of the NSW government's $21 million commitment
to support medicinal cannabis reforms. The new form of cannabis to
be used in the trial has been developed by the University of
Sydney's Lambert Initiative. CTC is the
coordinating centre for the trial.
The research team will be led by Clinical Associate Professor Peter
Grimison from the Chris O`Brien
Professor John Simes, CTC director, says: 'This new trial will
be directed by leading Australian cancer researchers. It will be
rigorously conducted and is expected to lead to high-quality
evidence on whether medicinal cannabis can improve the quality of
life of people being treated for cancer'.
In its first stage, the trial will involve up to 80 patients to
assess whether the drug can be successfully tolerated and to
establish the best dosage. The second stage of the trial will
involve more patients and will determine whether cannabis relieves
symptoms and improves quality of life.
The trial will recruit patients at Lifehouse and other hospitals
in NSW. Participants must be over 18 years of age.
Researchers from the Lambert Initiative and Chris O'Brien
Lifehouse have worked closely with Canadian company Tilray to
develop an oral medication in capsule form, containing the
cannabinoid molecules tetrahydrocannabinol and cannabidiol (THC and
Professor Nicholas Lintzeris from the Lambert Initiative, who
will be a clinical director of the trial, has said 'Synthetic
cannabinoid medications are licensed for this purpose in other
countries but this represents a major advance for cannabis-based
medications-an oral capsule with reliable doses of cannabinoids
extracted from cannabis plants, under pharmaceutical grade
conditions. In time, we expect to see an expanded range of cannabis
medication options for patients'.
26 February 2016